Cantor Fitzgerald reiterates Overweight rating on GH Research stock

GH Research PLC (GHRS) has received reiterated Buy/Overweight ratings and strong price targets from multiple analysts, including Cantor Fitzgerald, Stifel, and JMP Securities, following significant progress with the FDA regarding its Investigational New Drug (IND) application for GH001. All but one clinical hold concern for GH001 have been resolved, with the remaining issue (respiratory tract histology in rats) believed by GHRS to be species-specific, a key de-risking event. This development, coupled with the company's strategic positioning in the burgeoning interventional psychiatry market and increasing infrastructure for psychedelic therapies, underpins analysts' confidence in GHRS's substantial upside potential.

Analysis

GH Research PLC (GHRS) is experiencing a significant de-risking event centered on its Investigational New Drug (IND) application for its lead candidate, GH001. The company has successfully resolved all but one of the FDA's clinical hold concerns, with the final issue—respiratory tract histology findings in rats—believed by the company to be species-specific. This regulatory progress, following a complete response submission to the FDA in June, has triggered a wave of positive reinforcement from the analyst community. Cantor Fitzgerald, Stifel, JMP Securities, and Canaccord Genuity have all reiterated Buy or equivalent ratings, with price targets ranging from $25 to $40, implying substantial upside from its current $832 million market capitalization. The bullish outlook is further supported by favorable market dynamics in interventional psychiatry. The infrastructure for such therapies is rapidly expanding, evidenced by the doubling of Spravato clinics to approximately 6,000 in the last six months, which establishes crucial buy-and-bill systems and reimbursement codes that would benefit GH001 upon potential approval. Moreover, growing interest from hospitals in converting facilities for psychedelic therapies suggests a broadening addressable market beyond specialized clinics.

Key Decisions for Investors

• Given the resolution of most FDA clinical hold issues and strong analyst consensus, investors should evaluate the stock as a de-risked regulatory play with a clear catalyst pathway tied to the FDA's final decision.
• The key near-term event to monitor is the FDA's formal response to GH Research's submission; a positive outcome could unlock significant value, making it a critical binary event for the stock.
• Investors should track the growth and operational maturity of the interventional psychiatry market, particularly the expansion of clinics and establishment of reimbursement codes, as this infrastructure is a leading indicator of the commercial potential for GH001.